This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond. Dr Shubham Pant from MD Anderson Cancer Center, Houston Texas USA and Dr Jenny Seligmann from the University of Leeds, UK discuss treatment considerations in these patients and evaluate recent data. The experts discuss the treatments currently approved at third line – regorafenib and TAS-102 (trifluridine/tipiracil). They also reflect on data presented at ASCO GI 2023 from the SUNLIGHT trial which studied the use of TAS-102 plus bevacizumab as third-line treatment in refractory colorectal cancer and where this treatment may fit into the treatment sequence in the future. They also look at data from the FRESCO-2 trial which was presented at ESMO 2022 and studied fruquintinib in the later line mCRC setting.. The discussion then moves to treatments for molecularly selected mCRC patients with the MOUNTAINEER trial where a combination of trastuzumab and tucatinib was studied. Finally, they discuss EGFR rechallenge and data from the CRICKET and CHRONOS trials.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related